Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. (TNON) delivers innovative solutions for sacroiliac joint disorders through its Catamaran™ System. This page provides authorized updates on clinical advancements, regulatory milestones, and strategic developments directly from the company and verified sources.
Investors and medical professionals will find comprehensive coverage of FDA clearances, peer-reviewed study results, and partnership announcements. Our curated news collection features earnings reports, product launch details, and analysis of market expansion efforts in minimally invasive spine technology.
Key updates include progress in post-market clinical studies, intellectual property developments, and educational initiatives for surgeons. All content undergoes strict verification to ensure alignment with financial disclosure regulations and medical accuracy standards.
Bookmark this page for real-time updates on TNON's pioneering work in SI joint fusion technology. For direct access to corporate filings and investor resources, visit the official Tenon Medical website through our verified links.
Tenon Medical (NASDAQ:TNON) reported its Q4 and full-year 2024 financial results, showing mixed performance. Full-year revenue reached $3.3 million, marking a 12% increase from 2023, with improved gross profit of $1.7 million and gross margin of 52%.
Q4 2024 revenue remained flat at $0.8 million compared to Q4 2023, while gross profit decreased to $353,000 from $559,000, with margins declining to 46% from 69%. The company's Catamaran SI Joint Fusion System achieved significant milestones, including positive interim results from the MAINSAIL Study and completion of over 1,000 surgical procedures.
Notable developments include the expansion of their patent portfolio to twelve U.S. and international patents, successful initial clinical procedures with the new Catamaran SE platform, and securing an additional $3M in capital in March 2025. The company plans a national commercial launch of Catamaran SE in mid-2025.
Tenon Medical (NASDAQ:TNON), a company focused on sacroiliac joint disorders treatment, has secured $3.0 million in gross proceeds through a warrant inducement transaction with an existing healthcare-focused institutional investor. The agreement involves the immediate exercise of Series A and B Warrants for 2,445,700 total shares at a reduced price of $1.25 per share.
In exchange, the investor will receive new unregistered warrants in a private placement: Series C-1 Warrants for 2,445,700 shares and Series C-2 Warrants for 1,222,850 shares, both with a $1.25 exercise price. The C-1 Warrants will expire in 5 years and C-2 Warrants in 3 years from stockholder approval date. The transaction is expected to close around March 12, 2025.
The company plans to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction.
Tenon Medical (NASDAQ:TNON) has received approval for two additional patents from the European Patent Office for their Catamaran SI Joint Fixation Device. The patents, which will be granted within the European Community, are focused on the company's novel sacroiliac joint prostheses technology. According to Richard Ginn, Co-Founder and Chief Technology Officer, this approval strengthens Tenon's global patent portfolio and demonstrates their dedication to innovation in treating Sacroiliac Joint (SIJ) disorders.
Tenon Medical (NASDAQ:TNON), a company focused on Sacroiliac Joint (SIJ) disorders treatment, has scheduled its Q4 and full year 2024 financial results release for March 20, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day, featuring a Q&A session with its covering analyst.
The earnings call replay will be accessible through April 3, 2025, via Tenon's Investor Relations website or by telephone using the access code 13751490.
Tenon Medical (NASDAQ:TNON), a company focused on treating Sacroiliac Joint (SIJ) disorders, has announced that CFO Kevin Williamson will conduct one-on-one investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference week in San Francisco, starting January 13th, 2025.
The conference is recognized as the healthcare industry's premier global investment forum, featuring over 500 healthcare companies and bringing together executives, investors, and innovators from across the healthcare sector. The event showcases innovations in biotechnology, pharmaceuticals, and healthcare technologies.
Interested parties can schedule meetings with Tenon's management by contacting their investor relations team at tenon@mzgroup.us.
Tenon Medical has successfully completed initial clinical cases with its new Catamaran SE SI Joint Fixation Device across multiple centers in Idaho, Pennsylvania, Minnesota, Arizona, and Utah. The new implant features a 30% reduction in width compared to the original Catamaran device, making it suitable for smaller SI joint anatomy or revision surgeries. The device is a single, MRI-compatible titanium implant designed to stabilize and fuse the SI joint. Over 750 Catamaran fixation devices have been implanted to date for treating SI Joint dysfunction, sacroiliitis, and revision cases.
Tenon Medical (NASDAQ: TNON), a company focused on Sacroiliac Joint (SIJ) disorders treatment, has scheduled its Q3 2024 financial results release for November 13, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day, featuring a Q&A session with covering analysts. The call will be accessible via phone (1-800-717-1738 US, 1-646-307-1865 International) and webcast. A replay will be available through November 27, 2024, via the company's IR website or telephone.
Tenon Medical (NASDAQ:TNON), a company focused on Sacroiliac Joint (SIJ) disorders treatment, has announced full compliance with all Nasdaq continued listing requirements. The company has successfully addressed previous non-compliance issues related to independent directors, board committees, minimum bid price, public float shares, and stockholders' equity. Nasdaq has provided written confirmation of the company's renewed compliance status.
Tenon Medical, Inc. (NASDAQ:TNON) has announced the issuance of three new U.S. patents, further strengthening its international patent portfolio for Sacroiliac Joint (SIJ) stabilization systems. The patents include:
1. U.S. Patent Nos. 12,115,075 and 12,115,076: Enhanced Catamaran® prostheses with unique drug delivery compositions for improved sealing and bone growth.
2. U.S. Patent No. 12,115,077: SI joint prostheses designed to correct failed SI joint stabilization without removing the failed implant.
These additions bring Tenon's patent portfolio for the Catamaran® SI Joint Fusion System to 12 issued U.S. and foreign patents, with 23 pending applications. The company views these patents as reinforcing its focus on innovation and strengthening its competitive position in the industry.
Tenon Medical (NASDAQ:TNON) has announced the issuance of three Notices of Allowance from the USPTO for patent applications related to their Catamaran® SI Joint Fusion System. Two applications focus on unique drug delivery compositions for bone growth, while the third addresses correcting failed SI joint stabilization without removing the failed implant.
These additions will expand Tenon's patent portfolio to 9 granted patents and 26 pending applications worldwide. Richard Ginn, Co-Founder and CTO, emphasized the importance of intellectual property protection in their growth strategy and commitment to innovation in SI joint treatment.
FAQ
What is the current stock price of Tenon Medical (TNON)?
What is the market cap of Tenon Medical (TNON)?
